CLINICAL TRIALS PROFILE FOR CAPTOPRIL

All Clinical Trials for CAPTOPRIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004230 ↗	Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation	Completed	National Cancer Institute (NCI)	Phase 3	1999-10-01	RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients who are undergoing bone marrow or stem cell transplantation following chemotherapy and radiation therapy.
NCT00004230 ↗	Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation	Completed	Northwestern University	Phase 3	1999-10-01	RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients who are undergoing bone marrow or stem cell transplantation following chemotherapy and radiation therapy.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00077064 ↗	Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy	Terminated	National Cancer Institute (NCI)	Phase 2	2003-06-01	RATIONALE: Captopril is a drug that may be able to decrease side effects caused by radiation therapy, and may improve the quality of life of patients with non-small cell lung cancer or limited-stage small cell lung cancer. PURPOSE: This randomized phase II trial is studying how well captopril works in decreasing side effects and improving the quality of life in patients who have received radiation therapy with or without chemotherapy for stage I, stage II, or stage IIIB non-small cell lung cancer or limited-stage small cell lung cancer.
NCT00077064 ↗	Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy	Terminated	NRG Oncology	Phase 2	2003-06-01	RATIONALE: Captopril is a drug that may be able to decrease side effects caused by radiation therapy, and may improve the quality of life of patients with non-small cell lung cancer or limited-stage small cell lung cancer. PURPOSE: This randomized phase II trial is studying how well captopril works in decreasing side effects and improving the quality of life in patients who have received radiation therapy with or without chemotherapy for stage I, stage II, or stage IIIB non-small cell lung cancer or limited-stage small cell lung cancer.

Clinical Trial Conditions for CAPTOPRIL

Condition Name

Condition Name for CAPTOPRIL
Intervention	Trials
Hypertension	9
Diabetic Nephropathy	4
Healthy Volunteers	2
Primary Aldosteronism	2

Condition MeSH

Condition MeSH for CAPTOPRIL
Intervention	Trials
Hypertension	12
Kidney Diseases	5
Diabetic Nephropathies	5
Diabetes Mellitus	4

Clinical Trial Locations for CAPTOPRIL

Trials by Country

Trials by Country for CAPTOPRIL
Location	Trials
United States	47
Taiwan	4
Egypt	4
China	4
Brazil	3

Trials by US State

Trials by US State for CAPTOPRIL
Location	Trials
Ohio	6
Massachusetts	4
Tennessee	3
Illinois	3
Maryland	2

Clinical Trial Progress for CAPTOPRIL

Clinical Trial Phase

Clinical Trial Phase for CAPTOPRIL
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	15
Phase 3	6

Clinical Trial Status

Clinical Trial Status for CAPTOPRIL
Clinical Trial Phase	Trials
Completed	22
Unknown status	12
Not yet recruiting	8

Clinical Trial Sponsors for CAPTOPRIL

Sponsor Name

Sponsor Name for CAPTOPRIL
Sponsor	Trials
National Cancer Institute (NCI)	3
Novartis	3
VA Office of Research and Development	2

Sponsor Type

Sponsor Type for CAPTOPRIL
Sponsor	Trials
Other	57
Industry	10
U.S. Fed	4

Clinical Trials Update, Market Analysis, and Projection for Captopril

Last updated: October 27, 2025

---

Introduction

Captopril, an angiotensin-converting enzyme (ACE) inhibitor, originated as a groundbreaking antihypertensive agent approved in the early 1980s. Its therapeutic scope extends beyond hypertension to include heart failure, diabetic nephropathy, and certain types of renal disorders. As pharmacological landscapes evolve, understanding the latest clinical trials, market trends, and future projections for Captopril offers valuable insights amid rising competition and technological advances.

---

Clinical Trials Landscape for Captopril

Historical Context

Since its FDA approval in 1981, Captopril has been a staple in cardiovascular therapy. Early clinical trials demonstrated significant efficacy in reducing blood pressure and preventing renal disease progression. The drug's adoption was solidified through trials such as the CONSENSUS and the SOLVD studies, which confirmed its benefits in congestive heart failure and systolic dysfunction.

Current Clinical Trials Initiatives

In recent years, the focus of clinical trials involving Captopril has shifted from general hypertension to exploring nuanced indications, combination therapies, and pharmacogenomics. A review of ClinicalTrials.gov reveals:

• Hypertension and Heart Failure: Multiple ongoing Phase IV observational studies examine long-term safety and effectiveness across diverse populations, including diabetic patients and the elderly.

• Diabetic Nephropathy: Several trials investigate Captopril's role in delaying renal decline, often in combination with newer agents like SGLT2 inhibitors. These studies aim to redefine optimal dosing and timing strategies for renal protection.

• Combination Therapy and Drug Interactions: Trials are exploring synergistic effects of Captopril with other antihypertensives, such as calcium channel blockers and diuretics, to optimize blood pressure control while minimizing adverse effects.

• Pharmacogenomics and Personalized Medicine: Emerging studies assess genetic markers influencing Captopril responsiveness, allowing tailored treatment approaches.

Emerging Innovations and Challenges

Despite its proven efficacy, Captopril faces challenges including the development of newer ACE inhibitors and ARBs that may offer better tolerability. Moreover, the advent of neprilysin inhibitors (e.g., sacubitril/valsartan) has prompted comparative trials and led to re-evaluation of Captopril’s positioning.

---

Market Analysis of Captopril

Historical Market Performance

Initially, Captopril captured a dominant position in hypertension market segments, with high prescription volumes driven by its cost-effectiveness and proven efficacy. Major pharmaceutical players, such as Merck and Bristol-Myers Squibb, led promotional efforts in this domain.

Current Market Dynamics

The decline in Captopril's market share has been notable over the last decade, primarily due to the advent of newer ACE inhibitors (e.g., enalapril, ramipril) and ARBs (e.g., losartan, valsartan) offering improved side effect profiles, especially regarding cough and angioedema.

Nevertheless, Captopril remains relevant in specific niches:

• Low-Income and Developing Markets: Cost-effective generic formulations sustain demand.
• Renal and Heart Failure: Prescriptions persist, particularly where healthcare infrastructure limits access to newer agents.
• Established Prescriber Base: Long-term safety data and clinician familiarity maintain steady utilization.

Market Segments and Regional Insights

• North America and Europe: Market share diminishes due to preferring newer agents with superior side effect profiles.

• Asia-Pacific, Latin America, Africa: Captopril’s affordability sustains market participation, with generic options dominating procurement.

• Hospital-Administered Protocols: Captopril is frequently used in hospital settings for acute management, especially in resource-limited environments.

Market Forecast (2023-2030)

Analysts project a gradual decline in global Captopril sales, compounded by:

• Increased adoption of ARBs and novel combination therapies.
• Patent expirations and generic proliferation reducing prices further.
• Rising preference for drugs with fewer side effects.

However, in low-income and rural settings, demand remains stable owing to affordability and prior prescribing habits.

Projection Summary:

• Compound Annual Growth Rate (CAGR): Estimated contraction of approximately 3-4% annually in mature markets.
• Emerging Markets: Slight growth driven by generics and expanding healthcare infrastructure.
• Potential for Niche Revivals: Limited, unless new formulation strategies or combination regimens emerge.

---

Future Projections and Strategic Considerations

Regulatory and Patent Outlook

While the original patent for Captopril has long expired, manufacturers continue to hold exclusive rights for specific formulations or combination therapies. Patent expirations foster generic competition, intensifying price pressures.

Innovation and Reformulation Opportunities

Research could explore:

• Extended-release formulations for improved compliance.
• Fixed-dose combinations with other antihypertensives.
• Topical or alternative delivery systems, reducing systemic adverse effects.

Market Position and Competitive Landscape

Captopril’s future growth hinges on niche application and cost-sensitive settings. Its role as a comparator drug in clinical trials positions it as a reference standard, but market share erosion remains inevitable in developed nations.

Potential Impact of New Therapeutic Classes

Emerging therapies, such as neprilysin inhibitors and novel anti-inflammatory agents, may overshadow traditional ACE inhibitors, including Captopril. Nonetheless, combination therapies integrating Captopril remain relevant where affordability is paramount.

---

Key Takeaways

• Clinical Trials: Ongoing studies emphasize tailored renal and cardiovascular therapies, with pharmacogenomic insights promising personalized medicine advancements.
• Market Trends: Global demand for Captopril is waning in developed regions due to newer agents, but remains stable or growing slowly in emerging markets where cost remains critical.
• Strategic Outlook: Manufacturers focusing on generic manufacturing, formulations, and niche indications can sustain profitability. Innovation in delivery and combination therapies may enhance longevity.
• Competitive Position: The drug’s legacy status ensures its continued relevance, albeit with diminishing market influence, primarily driven by affordability and established efficacy.
• Future Rivals: Newer antihypertensives with improved side effect profiles will likely dominate mainstream markets, relegating Captopril to auxiliary or cost-sensitive segments.

---

FAQs

1. Is Captopril still prescribed for hypertension today?
   Yes. Despite competition from newer agents, it remains prescribed, especially in resource-limited settings or for specific indications like renal protection.

2. What are the main limitations of Captopril?
   Common side effects include dry cough and angioedema. It also has a shorter half-life compared to newer ACE inhibitors, requiring multiple doses.

3. Are there ongoing clinical trials to expand Captopril’s indications?
   Most current trials focus on optimized dosing, combination therapies, and pharmacogenomics rather than expanding indications, which are well-established.

4. Can Captopril be combined safely with newer antihypertensives?
   Yes, in controlled settings. Combination therapy requires monitoring, but studies support its use when indicated.

5. What is the outlook for Captopril in the next decade?
   Its role will diminish in high-income markets but will persist in low-income regions. Innovations or new formulations could rejuvenate its relevance in niche markets.

---

References

1. [1] U.S. Food and Drug Administration. "Captopril Highlights." 1981.
2. [2] ClinicalTrials.gov. "Studies involving Captopril." 2023.
3. [3] MarketResearch.com. "Global ACE Inhibitors Market." 2022.
4. [4] World Health Organization. "Essential Medicines List." 2021.
5. [5] IMS Health. "Pharmaceutical Market Trends." 2022.

---

Disclaimer: This analysis synthesizes publicly available data up to 2023. For investment or clinical decisions, consult primary sources or professional advisors.